0
selected
-
1.
A randomized controlled study for Yuanhu Zhitong dropping pills in the treatment of knee osteoarthritis.
Gu, Y, Huang, J, Guo, H, Song, X, Li, J, Shi, Y, Xie, X
Medicine. 2020;(24):e20666
-
-
Free full text
-
Abstract
BACKGROUND Knee osteoarthritis (KOA) is a common chronic disorder of knee and the leading cause of pain in the elderly with an overall prevalence of 50% in people over 60 years of age. This disease is an important factor affecting the quality of life of middle-aged and elderly people, and its main symptom is knee joint pain. Due to the pain, the knee joint activity function is limited, bringing great pain to patients, affecting their quality of life, effective prevention, and treatment of KOA is a modern medical problem. METHODS The 60 patients who met the inclusion criteria were randomly divided into the treatment group and the control group. In this study, single center, randomized control and equivalent clinical trial were used for treatment. The treatment group received Yuanhu Zhitong dropping pills within 4 weeks, and the control group received diclofenac sodium sustained-release capsule treatment within 4 weeks. The main measures were visual analogue scale (VAS), WOMAC osteoarthritis index score and gastrointestinal symptoms rating scale (GSRS).Secondary measures included biochemical markers and adverse reactions during treatment. RESULT The results of this trial will be published on the website of China Clinical Trial Registration Center (http://www.chictr.org.cn/searchprojen.aspx) and in peer-reviewed journals or academic conferences. CONCLUSIONS This study is to assess the efficacy and safety of Yuanhu Zhitong dropping pills for knee osteoarthritis (KOA). REGISTRATION PROSPERO (registration number ChiCTR1900024712).
-
2.
Clinical Therapeutic Effects of Aspirin in Combination with Fufang Danshen Diwan, a Traditional Chinese Medicine Formula, on Coronary Heart Disease: A Systematic Review and Meta-Analysis.
Huang, J, Tang, X, Ye, F, He, J, Kong, X
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2016;(5):1955-1963
Abstract
BACKGROUND/AIMS: Coronary heart disease is characterized by vascular stenosis or occlusion resulting in myocardial ischemia, hypoxia and necrosis. In China, the combination of aspirin and Fufang Danshen Diwan (FDD), a traditional Chinese medicine formula, has been suggested in the treatment of coronary heart disease. There have been several studies comparing the effectiveness of aspirin alone and in combination with FDD to treat coronary artery disease; however, it remains unclear whether combined aspirin therapy is superior. This study was thus designed to clarify this issue through a systematic review and meta-analysis. METHODS Databases including PubMed, EMBASE, China National Knowledge Infrastructure (CNKI) database, Wanfang Data and VIP Information were searched. Papers were reviewed systematically by two researchers and analyzed using Cochrane software Revman 5.1. RESULTS Fourteen randomized controlled trials enrolling 1367 subjects were included. Meta-analyses revealed that aspirin in combination with FDD was significantly more effective at alleviating angina pectoris and improving electrocardiogram (ECG) results relative to aspirin therapy alone, reflected by the summary effects for the clinical markedly effective (OR = 2.45; 95% CI 1.95-3.08) and the total effective (OR = 3.92; 95% CI 2.87-5.36) rates. In addition, combined aspirin and FDD was significantly more efficacious than aspirin monotherapy at improving blood lipid levels, as indicated by the following outcomes: 1) reduction of TC level (SMD -1.12; 95% CI -1.49 to -0.76); 2) reduction of TG level (SMD -0.94; 95% CI -1.15 to -0.74); 3) reduction of LDL level (SMD -0.68; 95% CI -0.88 to -0.48); and 4) improvement of HDL level (SMD 0.52; 95% CI 0.04 to 0.99 ). No serious adverse events were reported in any of the included trials. CONCLUSION The present meta-analysis demonstrated that aspirin in combination with FDD was more effective than aspirin alone for treating coronary heart disease. More full-scale randomized clinical trials with reliable designs are recommended to further evaluate the clinical benefits and long-term effectiveness of FDD for the treatment of coronary heart disease.
-
3.
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure.
Li, X, Zhang, J, Huang, J, Ma, A, Yang, J, Li, W, Wu, Z, Yao, C, Zhang, Y, Yao, W, et al
Journal of the American College of Cardiology. 2013;(12):1065-1072
Abstract
OBJECTIVES The purpose of this study was to assess the effects of qili qiangxin capsules in patients with chronic heart failure (CHF). BACKGROUND Qili qiangxin capsules are a traditional Chinese medicine that has been approved in China for the treatment of CHF, but the evidence supporting its efficacy remains unclear. METHODS A total of 512 patients with CHF were enrolled and randomly assigned to receive the placebo or qili qiangxin capsules in addition to their standard medications for the treatment of CHF. The primary endpoint was the reduction or percent change in the plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level during 12 weeks of treatment. RESULTS At the 12-week follow-up, a significant reduction in the NT-proBNP level from baseline was observed in both groups, but the qili qiangxin capsule group demonstrated a significantly greater reduction than the placebo group (p = 0.002); 47.95% of patients in the qili qiangxin capsule group demonstrated reductions in NT-proBNP levels of at least 30% compared with 31.98% of patients in the placebo group (p < 0.001). Treatment with qili qiangxin capsules also demonstrated superior performance in comparison to the placebo with respect to New York Heart Association functional classification, left ventricular ejection fraction, 6-min walking distance, and quality of life. CONCLUSIONS On a background of standard treatment, qili qiangxin capsules further reduced the levels of NT-proBNP. Together, our data suggest that qili qiangxin capsules could be used in combination therapy for CHF.
-
4.
[Erdi Biejia decoction for erectile dysfunction with kidney-yin deficiency].
Huang, J, Xu, FS
Zhonghua nan ke xue = National journal of andrology. 2012;(12):1143-6
Abstract
OBJECTIVE To observe the clinical efficacy of the Chinese medicine Erdi Biejia Decoction in the treatment of erectile dysfunction (ED) with kidney-yin deficiency, and explore its action mechanism and the nourishing yin doctrine in the treatment of ED. METHODS We equally randomized 60 ED patients with kidney-yin deficiency into a treatment and a control group, the former treated with oral Erdi Biejia Decoction, and the latter given placebo, for a course of 8 weeks. We compared the IIEF scores and levels of sex hormones T, E2, LH, FSH and PRL between the two groups before and after treatment. RESULTS Compared with the control group, the treatment group showed a significantly higher total effectiveness rate (36.67% vs 63.33%, P < 0.05), IIEF score (18.19 +/- 5.20 vs 23.08 +/-4.71, P < 0.05) and plasma T level (116.41 +/- 3.19 vs 20.14 +/- 2.99, P < 0.05), but remarkably lower levels of E2, LH, FSH and PRL (P < 0.05) after medication, all with statistically significant differences from pre-medication (P < 0.05). CONCLUSION Erdi Biejia Decoction is efficacious in the treatment of ED with kidney-yin deficiency, with no obvious adverse effects.
-
5.
[Effect of compound Polygonum multiflorum extract on Alzheimer's disease].
Chen, L, Huang, J, Xue, L
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. 2010;(6):612-5
Abstract
OBJECTIVE To observe the clinical effect of compound Polygonum multiflorum extract on Alzheimer's disease (AD). METHODS We collected 209 AD patients, among whom 120 were treated with compound Polygonum multiflorum extract as a treatment group, 60 were treated with Polygonum multiflorum extract as a Chinese herb control group, and 29 were treated with Naofukang as a western medicine control group. The scores for the Mini-Mental State Examination (MMSE), Ability of Daily Living Scale (ADL) and the therapeutic effect were assessed and compared before and after the 12 week treatment. RESULTS After the treatment the scores for MMSE and ADL were improved in all groups. The scores of MMSE and ADL in the compound Polygonum multiflorum extract treatment group were significantly improved compared with the Chinese herb control group and the western medicine control group (P < 0.01). The total effective rate of 93.33% in the compound Polygonum multiflorum extract treatment group was better than 73.33% in the Chinese herb control group and 68.97% in the western medicine control group (P < 0.01). CONCLUSION Compound Polygonum multiflorum extract has effect on AD, and it is superior to Polygonum multiflorum extractor Naofukang.